Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and relaxing because that oh-so-familiar routine of meetings, deadlines, conference calls, and the like has, of course, returned. Before we continue, though, we want to apologize for the late start. We were sidetracked by a bit of shoveling — there were mounds of snowing blanketing the Pharmalot campus and then a quick story to post, which leads off the list of items today. In any event, time for a cup of stimulation. Hope all goes well today and you conquer the world …

Eli Lilly (LLY) is introducing a new version of insulin called Lispro at half the list price as drug makers struggle with mounting criticism over the cost of prescription drugs, although insulin costs have generated particular anger among consumers, STAT writes. The new so-called authorized generic version of the Humalog insulin will sell for $137.35 a vial, while the list price of a five-pack of KwikPens will be $265.20. Lispro should be more affordable to the uninsured or those with high-deductible insurance plans, whose copays are typically tied to list prices.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy